Suppr超能文献

胃蛋白酶原 II 可作为 H. pylori 根除前后胃体形态变化的潜在替代标志物。

Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication.

机构信息

Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 1411713135, Iran.

Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985711151, Iran.

出版信息

Biomed Res Int. 2014;2014:481607. doi: 10.1155/2014/481607. Epub 2014 Jun 17.

Abstract

BACKGROUND

The aim of this investigation is to study the relationship between gastric morphology and serum biomarkers before and after Helicobacter pylori eradication.

METHODS

First-degree relatives of gastric cancer patients underwent gastroscopy before and 2.5 years after H. pylori eradication. The morphological changes in two categories (normal to mild and moderate to severe) were compared with level of pepsinogens I and II before eradication (n = 369), after eradication (n = 115), and in those with persistent infection (n = 250).

RESULTS

After eradication, pepsinogen I decreased to 70% and pepsinogen II to 45% of the previous values. Unlike pepsinogen II and pepsinogen I to II ratio that were affected by the severity of inflammation and atrophy in corpus in all groups, pepsinogen I generally did not change. After eradication, subjects with high mononuclear infiltration in corpus had lower pepsinogen I (54 versus 77.1 μ/mL), higher pepsinogen II (9.4 versus 6.9 μ/mL), and lower ratio (7.9 versus 11.6) than those without (P < 0.05).

CONCLUSION

Pepsinogen II is a good marker of corpus morphological changes before and after H. pylori eradication.

摘要

背景

本研究旨在探讨幽门螺杆菌(H. pylori)根除前后胃形态与血清生物标志物之间的关系。

方法

胃癌患者的一级亲属在 H. pylori 根除前和根除后 2.5 年进行胃镜检查。将两类形态变化(正常至轻度和中度至重度)与根除前(n=369)、根除后(n=115)和持续感染(n=250)时的胃蛋白酶原 I 和 II 水平进行比较。

结果

根除后,胃蛋白酶原 I 降至根除前的 70%,胃蛋白酶原 II 降至 45%。与胃体炎症和萎缩程度均影响胃蛋白酶原 II 和胃蛋白酶原 I 比值不同,胃蛋白酶原 I 一般不变。根除后,胃体单核细胞浸润较高者的胃蛋白酶原 I 较低(54 比 77.1 μ/mL),胃蛋白酶原 II 较高(9.4 比 6.9 μ/mL),比值较低(7.9 比 11.6)(P<0.05)。

结论

胃蛋白酶原 II 是 H. pylori 根除前后胃体形态变化的良好标志物。

相似文献

2
3
Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy.
Medicina (Kaunas). 2014;50(1):8-13. doi: 10.1016/j.medici.2014.05.001. Epub 2014 Jun 5.
5
Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication.
J Gastroenterol. 2009;44(8):819-25. doi: 10.1007/s00535-009-0066-2. Epub 2009 May 14.
7
Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori.
J Gastroenterol Hepatol. 2013 Jan;28(1):78-83. doi: 10.1111/j.1440-1746.2012.07285.x.
9
A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication.
PLoS One. 2017 Aug 30;12(8):e0183980. doi: 10.1371/journal.pone.0183980. eCollection 2017.
10
Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer.
Br J Cancer. 2013 Oct 29;109(9):2323-30. doi: 10.1038/bjc.2013.596. Epub 2013 Oct 8.

引用本文的文献

1
Serum metabolic profiling analysis of chronic gastritis and gastric cancer by untargeted metabolomics.
Ann Med Surg (Lond). 2024 Dec 19;87(2):583-597. doi: 10.1097/MS9.0000000000002977. eCollection 2025 Feb.
2
Analysis of high risk factors for chronic atrophic gastritis.
Saudi J Gastroenterol. 2023 Mar-Apr;29(2):127-134. doi: 10.4103/sjg.sjg_383_22.
3
Diagnostic performances of pepsinogens and gastrin-17 for atrophic gastritis and gastric cancer in Mongolian subjects.
PLoS One. 2022 Oct 17;17(10):e0274938. doi: 10.1371/journal.pone.0274938. eCollection 2022.
5
Identification of PGC-related ncRNAs and their relationship with the clinicopathological features of Gastric Cancer.
J Cancer. 2021 May 27;12(14):4389-4398. doi: 10.7150/jca.47787. eCollection 2021.
6
Incidence of Infection among Subjects with Helicobacter pylori Seroconversion.
Clin Endosc. 2022 Jan;55(1):67-76. doi: 10.5946/ce.2020.299. Epub 2021 Apr 1.
7
Giant Rugae in Helicobacter pylori-Infected Stomachs.
Clin Endosc. 2021 Jan;54(1):1-3. doi: 10.5946/ce.2021.007. Epub 2021 Jan 21.
8
Endoscopic Characteristics of Rugal Hyperplasia and Related Acid Condition in Helicobacter pylori-Infected Stomach.
Clin Endosc. 2021 Jan;54(1):73-84. doi: 10.5946/ce.2020.020. Epub 2020 Dec 15.

本文引用的文献

2
Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs.
J Gastroenterol Hepatol. 2011 Jun;26(6):1039-46. doi: 10.1111/j.1440-1746.2011.06692.x.
3
Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?
Ann Intern Med. 2009 Jul 21;151(2):121-8. doi: 10.7326/0003-4819-151-2-200907210-00009.
4
Screening for gastric cancer in Asia: current evidence and practice.
Lancet Oncol. 2008 Mar;9(3):279-87. doi: 10.1016/S1470-2045(08)70072-X.
6
7
Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study.
Scand J Gastroenterol. 2005 Mar;40(3):297-301. doi: 10.1080/00365520410010607.
9
ELECTROPHORETIC AND IMMUNOCHEMICAL DEMONSTRATION OF THE EXISTENCE OF FOUR HUMAN PEPSINOGENS.
J Clin Invest. 1964 Oct;43(10):1983-93. doi: 10.1172/JCI105072.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验